Investors may believe Sichuan Goldstone Asia Pharmaceutical Inc.'s strong earnings growth could underperform the market, causing its low P/E ratio. If recent earnings trends persist, a significant share price rise seems unlikely.

Sichuan Goldstone Asia Pharmaceutical's shift to profitability has likely led to a more positive market perception, evidenced by its share price growth. The overall sentiment around the company appears to have recently improved considering the increased total shareholder return (TSR).